Vuxen Group (VUXEN) Q2 25/26 earnings summary

Executive summary

• Achieved 8.4% year-over-year revenue growth in Q2, driven by focus on core sexual health segment and cost optimization.

• EBITDA margin improved to 10.3% in Q2, reflecting higher profitability and operational efficiency.

• Strong cash flow and liquidity position support continued selective investments in growth and profitability.

• Strategic focus on own brands and logistics infrastructure underpins long-term expansion in the Nordics and Europe.

Financial highlights

• Q2 net revenue: 57.6 MSEK (up from 53.1 MSEK), EBITDA: 5.9 MSEK (up from 3.2 MSEK), EBITDA margin: 10.3% (up from 5.9%).

• Six-month net revenue: 109.7 MSEK (up from 102.3 MSEK), EBITDA: 10.5 MSEK (up from 7.0 MSEK), EBITDA margin: 9.6% (up from 6.9%).

• Cash flow from operations for the period: 12.5 MSEK (up from 8.7 MSEK).

• Cash and cash equivalents at period end: 30.4 MSEK (up from 25.2 MSEK).

• Period result per share (EBITDA): 0.53 SEK for Q2, 0.94 SEK for six months.

Outlook and guidance

• Entering Q3 with strong momentum following successful Black Week and campaign periods.

• Continued focus on core segment and cost optimization expected to drive further profitability.

• Solid balance sheet and liquidity provide flexibility for future investments and shareholder value creation.